scholarly journals The Protein Tyrosine Phosphatase Non-receptor Type N22 (PTPN22) Gene Functional Polymorphism (1858T) is not Associated with Rheumatoid Arthritis in Kuwaiti Patients

2021 ◽  
Vol 15 (1) ◽  
pp. 45-50
Author(s):  
Adel M. Al-Awadhi ◽  
Mohammad Z. Haider ◽  
Jalaja Sukumaran ◽  
Eman AH Hasan ◽  
Youssef A. Bartella

Background: Rheumatoid Arthritis (RA) is a chronic disorder characterized by an inflammation of synovial tissue in joints resulting in pain, deformities and affects the quality of life. The gene for protein tyrosine phosphatase non-receptor type 22 (PTPN22) encodes a lymphoid specific phosphatase (LYP), which serves as a negative regulator of T lymphocyte activation and is associated with a number of autoimmune/chronic diseases in various ethnic groups. Objective: This study was undertaken to investigate an association between PTPN22 gene functional polymorphism (C1858T; rs2476601) and rheumatoid arthritis (RA) in Kuwaiti Arabs. The frequency of this candidate locus was compared between Kuwaiti RA patients and the controls and with that reported from other populations. Methods: The study was carried out in 191 Kuwaiti RA patients and 214 healthy controls. The diagnosis of RA was carried out according to the guidelines of the American College of Rheumatology (ACR). The genotypes of PTPN22 gene (C1858T) polymorphism were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and confirmed by DNA sequence analysis in RA patients and controls. Results: The TT genotype of PTPN22 gene functional polymorphism C1858T was found in 2/191 (1%) in RA patients compared to 2/214 (1%) in the controls (P = 1.0). In contrast, heterozygous CT genotype was detected in 3/191 (1.57%) RA patients compared to 32/214 (14.9%) in the controls. The CC genotype was detected in 186/191 (97.38%), RA patients while it was detected in 180/214 (84.1%) of the controls. The two RA patients who carried the homozygous variant (TT) genotype were both positive for rheumatoid factor (RF) and did not have any extra-articular manifestations. Amongst the Kuwaiti RA patients, 27% had a family history of RA. No correlation was found between the activity/severity of the disease and PTPN22 gene polymorphism genotypes. Conclusion: This study did not find an association between the PTPN22 gene functional polymorphism (C1858T) and clinical manifestation and activity/severity of RA in Kuwaiti Arabs. This is in sharp contrast to previous reports from Caucasian and some other populations in which a positive association of PTPN22 gene (C1858T) polymorphism with genetic susceptibility to RA has been reported.

2005 ◽  
Vol 22 (2) ◽  
pp. 169-175 ◽  
Author(s):  
Yoshimi Nakagawa ◽  
Naohito Aoki ◽  
Koji Aoyama ◽  
Hidehisa Shimizu ◽  
Hitoshi Shimano ◽  
...  

2013 ◽  
Vol 72 (Suppl 1) ◽  
pp. A69.1-A69
Author(s):  
Borbala Aradi ◽  
Maria Filkova ◽  
Stephanie Kasper ◽  
Kerstin Klein ◽  
Michael Scharl ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (58) ◽  
pp. 98798-98811 ◽  
Author(s):  
Xiaotang Yu ◽  
Fan Zhang ◽  
Jun Mao ◽  
Ying Lu ◽  
Jiazhi Li ◽  
...  

2021 ◽  
pp. jclinpath-2020-206927
Author(s):  
Maryam Ahmed Al Barashdi ◽  
Ahlam Ali ◽  
Mary Frances McMullin ◽  
Ken Mills

The leucocyte common antigen, protein tyrosine phosphatase receptor type C (PTPRC), also known as CD45, is a transmembrane glycoprotein, expressed on almost all haematopoietic cells except for mature erythrocytes, and is an essential regulator of T and B cell antigen receptor-mediated activation. Disruption of the equilibrium between protein tyrosine kinase and phosphatase activity (from CD45 and others) can result in immunodeficiency, autoimmunity, or malignancy. CD45 is normally present on the cell surface, therefore it works upstream of a large signalling network which differs between cell types, and thus the effects of CD45 on these cells are also different. However, it is becoming clear that CD45 plays an essential role in the innate immune system and this is likely to be a key area for future research. In this review of PTPRC (CD45), its structure and biological activities as well as abnormal expression of CD45 in leukaemia and lymphoma will be discussed.


2021 ◽  
Vol 26 ◽  
pp. 100974
Author(s):  
Shaoting Zhang ◽  
Liangying Zhang ◽  
Zongying Jiang ◽  
Yue Guo ◽  
Hui Zhao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document